RAND debuts tool to evaluate US health proposals

19 January 2009

The USA's RAND Corp has launched an on-line tool to provide policymakers and interested parties with a unique way of understanding and evaluating  the effects and unintended consequences of health care reform proposals  certain to be introduced in the new 111th Congress and beyond.

COMPARE (Comprehensive Assessment of Reform Efforts) is a  first-of-its-kind on-line resource that synthesizes what is known about  the current heath care system, provides information on proposals to  modify the system and delivers insight about how potential policy  changes are likely to affect health care delivery and costs in the USA.

The centerpiece of COMPARE is a policy options "dashboard" that offers  both a snapshot and an in-depth look at the implications that various  policy changes could have on a range of outcomes like costs to  government and others, quality of care and access to care, as well as  the ease with which changes could be implemented. The dashboard also  depicts gaps in our knowledge about the consequences of changes in our  health care system.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight